In patients presenting with their first ST-elevation myocardial infarction (STEMI), the interleukin-6 (IL-6) receptor inhibitor tocilizumab, significantly improved myocardial salvage, according to a study presented as late-breaking science Sunday at the European Society of Cardiology (ESC) 2020 virtual congress.